{
    "ticker": "SCYX",
    "name": "Scynexis, Inc.",
    "description": "Scynexis, Inc. is a biotechnology company focused on the development of innovative therapies for difficult-to-treat infections. Founded in 2000 and headquartered in Jersey City, New Jersey, Scynexis is dedicated to addressing the global health crisis posed by antifungal-resistant infections. The company\u2019s lead product, SCY-078, is a novel antifungal agent that has demonstrated efficacy against invasive fungal infections, including those caused by Candida and Aspergillus species. By leveraging its proprietary drug discovery platform, Scynexis aims to develop a pipeline of therapies that can improve patient outcomes and reduce the burden of resistance. The company is committed to advancing the science of antifungal treatments and is collaborating with healthcare professionals and institutions to enhance the understanding and management of fungal diseases. Scynexis also focuses on addressing unmet medical needs, particularly in immunocompromised patients, where treatment options are often limited. With a robust clinical development program and a vision to transform the treatment landscape of fungal infections, Scynexis is poised to make significant contributions to infectious disease management and public health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Jersey City, New Jersey, USA",
    "founded": "2000",
    "website": "https://www.scynexis.com",
    "ceo": "Erik E. E. Paul",
    "social_media": {
        "twitter": "https://twitter.com/scynexis",
        "linkedin": "https://www.linkedin.com/company/scynexis/"
    },
    "investor_relations": "https://ir.scynexis.com",
    "key_executives": [
        {
            "name": "Erik E. E. Paul",
            "position": "CEO"
        },
        {
            "name": "David Angulo",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antifungal Therapies",
            "products": [
                "SCY-078"
            ]
        }
    ],
    "seo": {
        "meta_title": "Scynexis, Inc. | Innovative Antifungal Therapies",
        "meta_description": "Explore Scynexis, Inc., a biotechnology company dedicated to developing novel antifungal therapies for challenging infections. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "Scynexis",
            "Antifungal Therapy",
            "Biotechnology",
            "Infectious Disease",
            "SCY-078"
        ]
    },
    "faq": [
        {
            "question": "What does Scynexis specialize in?",
            "answer": "Scynexis specializes in developing innovative therapies for difficult-to-treat infections, particularly antifungal therapies."
        },
        {
            "question": "What is SCY-078?",
            "answer": "SCY-078 is Scynexis' lead product, a novel antifungal agent aimed at treating invasive fungal infections."
        },
        {
            "question": "Where is Scynexis headquartered?",
            "answer": "Scynexis is headquartered in Jersey City, New Jersey, USA."
        },
        {
            "question": "When was Scynexis founded?",
            "answer": "Scynexis was founded in 2000."
        }
    ],
    "competitors": [
        "CLVS",
        "VRNA",
        "AZN"
    ],
    "related_stocks": [
        "GILD",
        "AMGN",
        "MRNA",
        "ABBV"
    ]
}